

CURRICULUM VITAE

Doris Voy Kan Quon

Orthopaedic Hemophilia Treatment Center
Orthopaedic Institute for Children
403 West Adams Blvd.
Los Angeles, CA 90007
(213) 742-1402 (clinic)
(213) 742-1103 (FAX)

Sarcoma Oncology Center
2811 Wilshire Blvd. Suite 414
Santa Monica, CA 90403
(310) 552-9999 (office)
(310) 201-6685 (FAX)

Education

1988-1996 University of California, Los Angeles. M.D.
1989-1995 University of California, Los Angeles. Ph.D. in Microbiology & Immunology
1982-1986 University of California, Los Angeles. BS in Biochemistry,
Magna cum Laude

Board Certification

1999 American Board of Internal Medicine
2002 American Board of Internal Medicine, Subspecialty of Oncology
2003 American Board of Internal Medicine, Subspecialty of Hematology
2010 Recertification: American Board of Internal Medicine
2013 Recertification: American Board of Internal Medicine, Subspecialty of Hematology

Licensure

CA License No. A065707 (expiration: 31 August 2019)
DEA No. BQ6076904

Training/Research/Work Experience

2009-present Medical Director, Hemophilia Treatment Center at Orthopaedic Hospital

2004-present Medical Oncologist, Sarcoma Oncology Center, Santa Monica, California

2008-2009 Co-director Director, Hemophilia Treatment Center at Orthopaedic Hospital

2005-2007 Associate Medical Director, Hemophilia Treatment Center at Orthopaedic Hospital

2003- 2004 Staff Hematologist at the Hemophilia Treatment Center at Orthopaedic Hospital

2000- 2003 Fellowship Research with Dr. Dennis Slamon, Dept. of Hematology/Oncology, UCLA. Her-2/*neu* overexpression and signal transduction.

1999- 2003 Fellowship in Hematology/Oncology – UCLA Medical Center

1996-1999 Internship and Residency in Internal Medicine – UCLA Medical Center

Training/Research/Work Experience (cont.)

- 1989-1995 Graduate Student Researcher with Dr. Patricia Johnson, Dept. of Microbiology & Immunology, UCLA. Drug resistance and gene expression in the protozoan parasite, *Trichomonas vaginalis*.
- 1988-1989 Medical Student Researcher with Dr. David Campbell, Dept. of Microbiology & Immunology, UCLA. Proteins that bind to the 3' end of the mini-exon gene of the protozoan parasite, *Trypanosoma brucei*.
- 1986-1988 Staff Research Associate for Dr. Elizabeth Neufeld, Dept. of Biological Chemistry, UCLA. Proteolytic processing of the alpha and beta subunits of the lysosomal enzyme, beta-hexosaminidase, in human fibroblasts.
- 1985-1986 Undergraduate Researcher with Dr. Elizabeth Neufeld/Dr. Paul Boyer, Dept. of Biological Chemistry, UCLA. Synthesis and processing of the alpha and beta subunits of the lysosomal enzyme, beta-hexosaminidase, in human fibroblasts from Tay Sachs and Sandhoff patients.
- 1984-1986 Laboratory Assistant for Dr. Harvey Herschman, Laboratory of Biomedical and Environmental Sciences, UCLA. Regulation of the rat metallothionein gene.

Honors and Awards

- 2002 ASCO Young Investigator Award
1994 AOA Medical Student Research Award
1992 Dr. Ursula Mandel Scholarship
1991 Hortense Fishbaugh Memorial Scholarship
1991 Women's University Club Scholarship
1990 Alumni Association Graduate Student Distinguish Scholar Award
1988 NIH Medical Student Training Program Fellowship
1986 *Phi Beta Kappa*
1986 Chemistry/Biochemistry Departmental Honors
1985 Cook Scholarship
1984 UCLA Women's Faculty Club Scholarship
1982 Chancellor's Scholarship

Medical Societies and Memberships

- Hemophilia Foundation of Southern California, Medical Director
International Society of Thrombosis and Haemostasis
American Society of Hematology
American Society of Clinical Oncology
National Hemophilia Foundation
Hemostasis and Thrombosis Research Society

Publications

Sood SL, Cheng D, Ragni M, Kessler CM, **Quon D**, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissing C, Galdzicka S, Corson M, Watson C, Konkle BA. (2018) A cross-sectional analysis of cardiovascular disease in the hemophilia population. *Blood Adv.* Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

Buckner TW, Batt K, **Quon D**, Witkop M, Recht M, Kessler C, Baumann K, Hernandez G, Wang M, Cooper DL, Kempton CL. (2018) Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. *Eur J Haematol.* Apr;100 Suppl 1:5-13. doi: 10.1111/ejh.13027.

Batt K, Boggio L, Neff A, Buckner TW, Wang M, **Quon D**, Witkop M, Recht M, Kessler C, Iyer NN, Cooper DL. (2018) Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. *Eur J Haematol.* Apr;100 Suppl 1:14-24. doi: 10.1111/ejh.13028.

Zhou JY, Rappazzo KC, Volland L, Barnes RFW, Brackman M, Steiner B, Kruse-Jarres R, **Quon DV**, Bailey C, Chang EY, von Drygalski A. (2018) Pocket handheld ultrasound for evaluation of the bleeding haemophilic joint: A novel and reliable way to recognize joint effusions. *Haemophilia.* Mar;24(2):e77-e80. doi: 10.1111/hae.13429. Epub 2018 Feb 12.

Kempton CL, Recht M, Neff A, Wang M, Buckner TW, Soni A, **Quon D**, Witkop M, Boggio L, Gut RZ, Cooper DL. (2018) Impact of pain and functional impairment in US adults with haemophilia: Patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study. *Haemophilia.* Mar;24(2):261-270. doi: 10.1111/hae.13377. Epub 2017 Dec 8.

Collins PW, **Quon DVK**, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobnic B, Hua Y, Babinchak TJ, Gomperts ED. (2017) Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. *Haemophilia.* 2017 Aug 17. doi: 10.1111/hae.13324. [Epub ahead of print]

Wang M, Lawrence JB, **Quon DV**, Ducore J, Simpson ML, Boggio LN, Mitchell IS, Yuan G, Alexander WA, Schved JF. (2017) PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. *Haemophilia.* 2017 Aug 3. doi: 10.1111/hae.13301. [Epub ahead of print]

Neufeld EJ, Solimeno L, **Quon D**, Walsh C, Seremetis S, Cooper D, Iyer NN, Hoxer CS, Giangrande P. (2017) Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices. *Haemophilia.* Jul 27. doi: 10.1111/hae.13279. [Epub ahead of print] Review.

Publications (cont.)

Witkop M, Neff A, Buckner TW, Wang M, Batt K, Kessler CM, **Quon D**, Boggio L, Recht M, Baumann K, Gut RZ, Cooper DL, Kempton CL (2017) Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. *Haemophilia*. Jul;23(4):556-565. doi: 10.1111/hae.13214. Epub 2017 Apr 16

Shapiro AD, Mahlangu JN, Perry D, Pasi J, **Quon DV**, Chowdary P, Tsao E, Li S, Innes A, Pierce GF, Allen GA. (2017) Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. *Haemophilia*. May;23(3):392-399. doi: 10.1111/hae.13144. Epub 2017 Feb 20.

Barnes RF, Cramer TJ, Sait AS, Kruse-Jarres R, **Quon DV**, von Drygalski A. (2016) The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study. *Int J Hypertens*. 2016:2014201. Epub 2016 Nov 14.

Quon DV, Klamroth R, Kulkarni R, Shapiro AD, Baker RI, Castaman G, Kerlin BA, Tsao E, Allen G. (2016) Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIII Fc) in the A-LONG and Kids A-LONG Studies. *Haemophilia*. Jan;23(1):e39-e42. doi: 10.1111/hae.13125. Epub 2016 Dec 11.

Wang M, Álvarez-Román MT, Chowdary P, **Quon DV**, Schafer K. (2016) Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports. *Blood Coagul Fibrinolysis*. Oct;27(7):737-744. Review.

Quon D, Chitlur M, Rajpurkar M, Simpson M, O'Brien S, Flood V, Hsieh L, Acharya S, Kruse-Jarres R, Sood S, Maahs J. (2016) Women leaders in hematology: Inspirations & insights. *Am J Hematol*. Apr;91 Suppl 1:S6-S34. doi: 10.1002/ajh.24316

Quon D, Reding M, Guelcher C, Peltier S, Witkop M, Cutter S, Buranahirun C, Molter D, Jane Frey M, Forsyth A, Tran DB, Curtis R, Hiura G, Levesque J, de la Riva D, Compton M, Iyer NN, Holot N, Cooper DL. (2015) Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia. *Am J Hematol*. Dec;90 Suppl 2:S17-22.

Witkop M, Guelcher C, Forsyth A, **Quon D**, Hawk S, Curtis R, Cutter S, Molter D, Cooper DL. (2015) Challenges in transition to adulthood for young adult patients with **hemophilia**: Quantifying the psychosocial issues and developing solutions. *Am J Hematol*. Dec;90 Suppl 2:S1-2.

Chawla SP, Chua VS, Hendifar AF, **Quon DV**, Soman N, Sankhala KK, Wieland DS, Levitt DJ. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. *Cancer*. (2015) Feb 15;121(4):570-9.

Publications (cont.)

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, **Quon DV**, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF. (2014) Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. *J Thromb Haemost.* Nov;12(11):1788-800.

von Drygalski A, Kolaitis NA, Bettencourt R, Bergstrom J, Kruse-Jarres R, **Quon DV**, Wassel C, Li MC, Waalen J, Elias DJ, Mosnier LO, Allison M. (2013) Prevalence and risk factors for hypertension in hemophilia. *Hypertension.* 62(1):209-15

Martinowitz U, Shapiro A, **Quon DV**, Escobar M, Kempton C, Collins PW, Chowdary P, Makris M, Mannucci PM, Morfini M, Valentino LA, Gomperts E, Lee M. (2012) Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. *Haemophilia.* 6(6):881-7.

Kruse-Jarres R, **Quon D**, Schramm W, Dolan G. (2012) Management of bleeding disorders in the elderly *Haemophilia.* May;18 Suppl 2:37-45.

Powell JS, Josephson NC, **Quon D**, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. (2012) Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. *Blood.* 29;119(13):3031-7.

Valentino LA, Mamonov V, Hellmann A, **Quon DV**, Chybicka A, Schroth P, Patrone L, Wong WY; for the Prophylaxis Study Group. (2012) A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. *J Thromb Haemost.* 10(3):359-367

Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, **Quon D**, Aledort L. (2011) The Use of a Single Von Willebrand Factor-Containing, Plasma-Derived FVIII Product in Hemophilia A Immune Tolerance Induction - U.S. Experience. *J Thromb Haemost.* 9(11):2229-34

Forsyth AL, **Quon DV**, Konkle BA. (2011) Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis. *Haemophilia.* 17(5):e870-6

Quon, D.V.K. and Logan, L. (2011) Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine[®] SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. *Haemophilia* 1:196-201.

Chawla SP, Chua VS, Fernandez L, **Quon D**, Blackwelder WC, Gordon EM, Hall FL. (2010) Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. *Mol Ther.* 18(2):435-41.

Publications (cont.)

Quon, D.V. and Konkle, B.A. (2009) How We Treat: Hematuria in Adults with Hemophilia. *Haemophilia* **16**(4):683-5.

Konkle, B.A., Kessler, C., Aledort, L., Andersen, J., Fogarty, P., Kouides, P., **Quon, D.**, Ragni, M., Zakarija, A., Ewenstein, B. (2009) Emerging Clinical Concerns in the Aging Hemophilia Patient. *Haemophilia* **15**(6):1197-1209.

Chawla SP, Chua VS, Fernandez L, **Quon D**, Saralou A, Blackwelder WC, Hall FL, Gordon EM. (2009) Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. *Mol Ther.* **17**(9):1651-7.

Breinich M.S., Ferguson D.J., Foth B.J., van Dooren G.G., Lebrun M, **Quon, D.V.**, Striepen B., Bradley P.J., Frischknecht F., Carruthers V.B., Meissner M. (2009) A Dynamin Is Required for the Biogenesis of Secretory Organelles in *Toxoplasma gondii*. *Curr Biol.* **19** 277-286

Silva, M, Luck JR, J. V., **Quon, D.**, Young, C. R., Chin, D. M., Ebrahimzadeh E. and Fong Y.-J. (2008) Inter- and intra-observer reliability of radiographic scores commonly used for the evaluation of haemophilic arthropathy. *Haemophilia* **14**(3) 504-12.

Saab, S., Cho.,D., **Quon D.V.**, Ibrahim, A.B., Dong, P. , Marder, V., and Logan, L. (2004) Same Day Outpatient Transjugular Liver Biopsies in Hemophilia. *Haemophilia.* **10**(6): 727-31

Quon, D.V.K., Delgadillo, M.G. and Johnson, P.J. (1996) *Trichomonas vaginalis* protein-coding genes are transcribed by an alpha-amanitin resistant RNA polymerase. *J. Mol. Evol.* **43**(3)253-62.

Quon, D.V.K., Delgadillo, M.G., Khachi, A., Smale, S.T. and Johnson, P.J. (1994) Similarity between a ubiquitous promoter element in an ancient eukaryote and mammalian initiator elements. *Proc. Natl. Acad. Sci U.S.A.* **91**(10):4579-4583.

Quon, D.V.K., de'Oliviera, C.E. and Johnson, P.J. (1992) Reduced transcription of the ferredoxin gene in metronidazole-resistant *Trichomonas vaginalis*. *Proc. Natl. Acad. Sci U.S.A.* **89**(10):4402-4406.

Dlott, B., d'Azzo, A., **Quon, D.V.K.** and Neufeld, E.F. (1990) Two mutations produce intron insertion in mRNA and elongated beta-subunit of the human beta-hexosaminidase. *J. Biol. Chem* **265**(29):17921-17927.

Quon, D.V.K., Proia, R.L., Bleibaum, J., Fowler, A.V. and Neufeld, E.F. (1989) Proteolytic processing of the beta-subunit of the lysosomal enzyme, beta-hexosaminidase, in normal human fibroblasts. *J. Biol. Chem.* **264**(6):3380-3384.

Little, L.E., Lau, M.M.H., **Quon, D.V.K.**, Fowler, A.V. and Neufeld, E.F. (1988) Proteolytic processing of the alpha-subunit of the lysosomal enzyme, beta-hexosaminidase, in normal human fibroblasts. *J. Biol. Chem.* **263**(9):4288-4292.